Last reviewed 2026-04-20 · How we verify

Vumide (CINROMIDE)

Phase 2 active Small molecule

Vumide (generic name: CINROMIDE) is a drug. It is currently in Phase 2 development.

Vumide works by binding to the sodium-dependent neutral amino acid transporter B(0)AT1, which is involved in the transport of certain amino acids across cell membranes.

Vumide (CINROMIDE) is a small molecule modality targeting the sodium-dependent neutral amino acid transporter B(0)AT1. Its mechanism of action and approved indications are not well-documented, and it is unclear if it has received FDA approval. The commercial status of Vumide is also unknown, with no information available on generic manufacturers or patent status. Further research is needed to understand the pharmacological properties and clinical applications of Vumide. As a result, key safety considerations and pharmacokinetic parameters, such as half-life and bioavailability, are currently unknown.

Likelihood of approval

16.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Immunology slight uplift +1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CINROMIDE
Target	Sodium-dependent neutral amino acid transporter B(0)AT1
Modality	Small molecule
Therapeutic area	Immunology
Phase	Phase 2

Mechanism of action

Think of it like a delivery truck that brings essential nutrients into cells. Vumide blocks this delivery truck, which can help reduce inflammation and other symptoms in certain conditions. By blocking the transport of amino acids, Vumide may help reduce the activity of certain cells that contribute to disease.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Vumide CI brief — competitive landscape report
Vumide updates RSS · CI watch RSS

Frequently asked questions about Vumide

What is Vumide?

Vumide (CINROMIDE) is a Small molecule drug.

How does Vumide work?

Vumide works by binding to the sodium-dependent neutral amino acid transporter B(0)AT1, which is involved in the transport of certain amino acids across cell membranes.

What is the generic name of Vumide?

CINROMIDE is the generic (nonproprietary) name of Vumide.

What development phase is Vumide in?

Vumide is in Phase 2.

What does Vumide target?

Vumide targets Sodium-dependent neutral amino acid transporter B(0)AT1.

Target: All drugs targeting Sodium-dependent neutral amino acid transporter B(0)AT1
Therapeutic area: All drugs in Immunology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing